We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Diagnosis of CF Simplified by Sweat Sensor Device

By LabMedica International staff writers
Posted on 24 Apr 2017
A wristband-type wearable sweat sensor that measures calcium and glucose levels and transmits the data to a central laboratory is expected to simplify the current diagnostic method for cystic fibrosis (CF).

Conventional methods for diagnosing cystic fibrosis require that patients visit a specialized center and wait for up to 30 minutes while electrodes stimulate sweat glands in the skin to provide enough perspiration for the test. More...
Then a laboratory measures the level of chloride ions in the sample to determine if the subject has the disease.

In contrast, the wearable sweat sensor stimulates the skin to produce small amounts of sweat, rapidly measures components in the sample, and sends the data by way of a cell phone to a laboratory that analyzes and returns the results.

To demonstrate the clinical value of the platform, human subject studies were performed in the context of the cystic fibrosis diagnosis and preliminary investigation of the blood/sweat glucose correlation. With the platform, the investigators detected the elevated sweat electrolyte content of cystic fibrosis patients compared with that of healthy control subjects. Furthermore, the results indicated that oral glucose consumption in the fasting state was followed by increased glucose levels in both sweat and blood.

"This is a huge step forward," said contributing author Dr. Carlos Milla, associate professor of pediatrics at Stanford University. "The test happens all at once and in real time. CF diagnosis, as well as other kinds of diagnoses, could be done without needing a staff of skilled clinicians on duty and a well-equipped lab. You can get a reading anywhere in the world."

The device was described in the April 17, 2017, online edition of the journal Proceedings of the [U.S.] National Academy of Sciences.


New
Gold Member
Neonatal Heel Incision Device
Tenderfoot
New
Gold Member
STI Test
Vivalytic MG, MH, UP/UU
New
HPV Molecular Test
BD Onclarity HPV Assay
New
Rapid Sepsis Test
SeptiCyte RAPID
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image

Urine-Based Multi-Cancer Screening Test Receives FDA Breakthrough Device Designation

Early detection across multiple cancers remains a major unmet need in population screening. Non-invasive approaches that can be delivered at scale may broaden access and shift diagnoses to earlier stages.... Read more

Molecular Diagnostics

view channel
Image: The new approach focuses on CpG DNA methylation, a chemical modification of cytosine and guanine bases, using tumor samples to develop a computational model that distinguishes among 21 cancer types (photo credet: 123RF)

Machine Learning Model Uses DNA Methylation to Predict Tumor Origin in Cancers of Unknown Primary

Cancers of unknown primary (CUP) are metastatic malignancies in which the primary site cannot be identified, complicating treatment selection. Many patients consequently receive broad, nonspecific chemotherapy... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.